Reports Q1 revenue $13.8M, consensus $14.01M. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics (SAGE). “We remain focused on establishing ZURZUVAE as the standard of care for women with postpartum depression and driving our business strategy forward with the goal of creating value for shareholders.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Is SAGE a Buy, Before Earnings?
- Cautious Outlook on SAGE Therapeutics: Hold Rating Maintained Amid EPS Adjustments and Revenue Forecast Revisions
- Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
- Sage Therapeutics resumed with an Underperform at BofA
- SAGE Therapeutics Announces CMO Resignation and Interim Appointment